Effect of probiotics in Nonalcoholic Fatty Liver
Phase 3
Recruiting
- Conditions
- K76.0onalcoholic Fatty Liver.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT20231229060558N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
People between 20 and 75 years old with confirmed fatty liver in Persian Cohort of Mashhad
Exclusion Criteria
•Liver failure
• Suffering from hepatitis (viral, autoimmune, metabolic, medicinal)
• History of alcohol consumption
• People with ALT or AST more than 5 times normal •
• Pregnant people
•Taking drugs that can cause hepatic steatosis, including antiarrhythmic drugs (Amiodarone) ), anti-metabolite antineoplastic drugs (methotrexate), hormonal antineoplastic drugs (tamoxifen), corticosteroids, anticonvulsant drugs, antiretroviral drugs
• use of antihypertensive drugs, vastatins)
• known hereditary defects (iron and copper). Storage diseases and alpha 1 antitrypsin deficiency
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of people with non-alcoholic fatty liver disease with a score of at least 2. Timepoint: Examining tests three months after start of using probiotics. Method of measurement: Liver tests including sugar and fat profile, ultrasound of the liver and bile ducts, and fibroscan of the liver.
- Secondary Outcome Measures
Name Time Method